ID: ALA1190520

Max Phase: Preclinical

Molecular Formula: C23H29NO3

Molecular Weight: 367.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)[C@@H]1CCCN(CCOCCC(c2ccccc2)c2ccccc2)C1

Standard InChI:  InChI=1S/C23H29NO3/c25-23(26)21-12-7-14-24(18-21)15-17-27-16-13-22(19-8-3-1-4-9-19)20-10-5-2-6-11-20/h1-6,8-11,21-22H,7,12-18H2,(H,25,26)/t21-/m1/s1

Standard InChI Key:  DEGMILQNXHRUSN-OAQYLSRUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 367.49

Molecular Weight (Monoisotopic): 367.2147

AlogP: 4.02

#Rotatable Bonds: 9

Polar Surface Area: 49.77

Molecular Species: ZWITTERION

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.61

CX Basic pKa: 9.28

CX LogP: 1.52

CX LogD: 1.52

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.68

Np Likeness Score: -0.71

References

1. Sindelar M, Lutz TA, Petrera M, Wanner KT..  (2013)  Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,  56  (3): [PMID:23336362] [10.1021/jm301800j]

2. Jurik A, Zdrazil B, Holy M, Stockner T, Sitte HH, Ecker GF..  (2015)  A binding mode hypothesis of tiagabine confirms liothyronine effect on γ-aminobutyric acid transporter 1 (GAT1).,  58  (5): [PMID:25679268] [10.1021/jm5015428]

Source

Source(1):

• Scientific Literature